22 generics for Atozet by Chong Kun Dang were approved

Collusion controversy

MSD’s Atozet, generics of 22 companies were approved following Chong Kun Dang

The products of 22 companies for hyperlipidemia (Ezetimibe/Atorvastatin) consigned by Chong Kun Dang were approved on the 8th.

 

As a result, 20 generisc within the same ingredient were approved, and the next drug price application for the same drug product was reduced to the lowest price.

 

This is because of the stepped drug price system that has been in effect since July of last year.

 

On the 8th, the MFDS approved 22 companies' Ezetimibe/Atorvastatin combination.

 

The companies are Kyongbo, Dongkoo Bio, Celltrion, Yooyoung, YuYu, Kukje, DongKook, Boryung, Samjin, SCD, Ahn-gook, Arlico, Alvogen Korea, SK Chemicals, HK inno.N, Wooridul, Reyon, Jinyang, Hana, Korea United, Korea Prime, and Hutecs.

 

It also includes Dongkoo Bio, which has completed the development of generic and recruited contractors.

 

Chong Kun Dang was approved in October as a drug for data-based re-evaluation through its own development of Ezetimibe/Atorvastatin.

 

MSD Korea's original Atozet was approved before the expiration of PMS.

 

Atozet's PMS will end on the 22nd of this month.

 

Chong Kun Dang also recruited a commissioned generic company.

 

Considering the drug price, more than 20 companies were recruited.

 

This is because if it is less than 20, the next licensed generic drug can also receive the highest price within 20.

 

Chong Kun Dang and consigned pharmaceutical companies promised that Chong Kun Dang would recruit 20 generic companies.

 

In the current drug price system, if more than 20 active ingredients are listed, the upper limit of the newly listed item will drop to 85% of the existing lowest price.

 

Some generic companies said they would file a complaint with the Fair Trade Commission, claiming that Chong Kun Dang and consignment manufacturers are fixing drug prices.

 

They said that if the related companies voluntarily report, they will be excluded from the complaint.

 

However, there was no company that voluntarily reported.

 

The issue of preemption of drug prices through consignment of a drug for data-based re-evaluation led to controversy over revision of the law.

 

Some lawmakers argued that there is a need to limit the number of drugs for data-based re-evaluation as well as generics.

 

Jeong-sook Seo, a member of People Power Party Rep also proposed a related bill.

 

However, small and medium-sized pharmaceutical companies strongly oppose it, and the MFDS, the ministry in charge, is also cautious about this.

 

Therefore, the revision of the law is not expected to be easy.

 

Chong Kun Dang changed the name of the previously approved product.

 

The first licensed product name is used by Kyongbo.

 

Lipilou is a blockbuster hyperlipidemia treatment sold by Chong Kun Dang.

 

The use of the company's product name is a strategy to increase the awareness of the new product to existing customers.

 

Chong Kun Dang's active marketing is expected.

 

Chong Kun Dang is also jointly selling the original Atozet, and it is noteworthy whether there will be any changes due to the release of Chong Kun Dang's new product name.